Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes

Journal of Diabetes and its Complications

Volumn 29, Issue 1, 2015, Pages 93-98

  Bakhtiani, P A ^a   El Youssef, J ^a   Duell, A K ^a   Branigan, D L ^a   Jacobs, P G ^b   Lasarev, M R ^a   Castle, J R ^a   Ward, W K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

Artificial pancreas; Closed Loop; Glucagon; Hypoglycemia; Type 1 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; GLUCOSE BLOOD LEVEL;

ACCURACY; ADULT; AGE; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NAUSEA; SENSOR; VOMITING; WEIGHT; AUTOMATION; BLOOD; BODY WEIGHT; COHORT ANALYSIS; COMPARATIVE STUDY; DEVICE SAFETY; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; EQUIPMENT DESIGN; HYPERGLYCEMIA; IMPLANTABLE INFUSION PUMP; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AUTOMATION; BLOOD GLUCOSE; BODY WEIGHT; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; EQUIPMENT DESIGN; EQUIPMENT SAFETY; FEMALE; GLUCAGON; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION PUMPS, IMPLANTABLE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84920520373     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.09.001     Document Type: Article

References (38)

1. J. Aman, and L. Wranne Hypoglycaemia in childhood diabetes. II. Effect of subcutaneous or intramuscular injection of different doses of glucagon Acta Paediatrica Scandinavica 77 4 1988 548 553
2. Anon Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group Diabetes 46 2 1997 271 286
3. Anon Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group New England Journal of Medicine 342 6 2000 381 389
4. Anon Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy JAMA, the Journal of the American Medical Association 290 16 2003 2159 2167
5. P.A. Bakhtiani, L.M. Zhao, J. El Youssef, J.R. Castle, and W.K. Ward A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy Diabetes, Obesity & Metabolism 15 12 2013 1065 1070
6. R.M. Bergenstal, D.C. Klonoff, S.K. Garg, B.W. Bode, M. Meredith, and R.H. Slover Threshold-based insulin-pump interruption for reduction of hypoglycemia New England Journal of Medicine 369 3 2013 224 232
7. G.B. Bolli, G.D. Dimitriadis, G.B. Pehling, B.A. Baker, M.W. Haymond, and P.E. Cryer Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus New England Journal of Medicine 310 26 1984 1706 1711
8. N. Caputo, J.R. Castle, C.P. Bergstrom, J.M. Carroll, P.A. Bakhtiani, and M.A. Jackson Mechanisms of glucagon degradation at alkaline pH Peptides 45 2013 40 47
9. J.R. Castle, J.M. Engle, J. El Youssef, R.G. Massoud, and W.K. Ward Factors influencing the effectiveness of glucagon for preventing hypoglycemia Journal of Diabetes Science and Technology 4 6 2010 1305 1310
10. J.R. Castle, J.M. Engle, J. El Youssef, R.G. Massoud, K.C. Yuen, and R. Kagan Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes Diabetes Care 33 6 2010 1282 1287
11. A.D. Cherrington, J.L. Chiasson, J.E. Liljenquist, A.S. Jennings, U. Keller, and W.W. Lacy The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog Journal of Clinical Investigation 58 6 1976 1407 1418
12. W.L. Clarke, and B. Kovatchev Continuous glucose sensors: Continuing questions about clinical accuracy Journal of Diabetes Science and Technology 1 5 2007 669 675
13. J. El Youssef, J.R. Castle, D.L. Branigan, R.G. Massoud, M.E. Breen, and P.G. Jacobs A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes Journal of Diabetes Science and Technology 5 6 2011 1312 1326
14. F.H. El-Khatib, S.J. Russell, D.M. Nathan, R.G. Sutherlin, and E.R. Damiano A bihormonal closed-loop artificial pancreas for type 1 diabetes Science Translational Medicine 2 27 2010 27ra27
15. D. Elleri, D.B. Dunger, and R. Hovorka Closed-loop insulin delivery for treatment of type 1 diabetes BMC Medicine 9 120 2011 10.1186/1741-7015-9-120
16. N. Flattem, K. Igawa, M. Shiota, M.G. Emshwiller, D.W. Neal, and A.D. Cherrington Alpha- and beta-cell responses to small changes in plasma glucose in the conscious dog Diabetes 50 2 2001 367 375
17. X. Gao, H. Ning, and Y. Wang Systematically in silico comparison of unihormonal and bihormonal artificial pancreas systems Computational and Mathematical Methods in Medicine 2013 2013 712496
18. S. Garg, R.L. Brazg, T.S. Bailey, B.A. Buckingham, R.H. Slover, and D.C. Klonoff Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: The in-clinic ASPIRE study Diabetes Technology & Therapeutics 14 3 2012 205 209
19. B. Gopakumaran, H.M. Duman, D.P. Overholser, I.F. Federiuk, M.J. Quinn, and M.D. Wood A novel insulin delivery algorithm in rats with type 1 diabetes: The fading memory proportional-derivative method Artificial Organs 29 8 2005 599 607
20. A. Haidar, L. Legault, M. Dallaire, A. Alkhateeb, A. Coriati, and V. Messier Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: A randomized crossover controlled trial CMAJ 185 4 2013 297 305
21. M. Hartley, M.J. Thomsett, and A.M. Cotterill Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: The Brisbane experience Journal of Paediatrics and Child Health 42 3 2006 108 111
22. M.W. Haymond, and B. Schreiner Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes Diabetes Care 24 4 2001 643 645
23. P. Herrero, P. Georgiou, N. Oliver, D.G. Johnston, and C. Toumazou A bio-inspired glucose controller based on pancreatic beta-cell physiology Journal of Diabetes Science and Technology 6 3 2012 606 616
24. R. Hovorka Closed-loop insulin delivery: From bench to clinical practice Nature Reviews. Endocrinology 7 7 2011 385 395
25. P.G. Jacobs, J. El Youssef, J. Castle, P. Bakhtiani, D. Branigan, and M. Breen Automated control of an adaptive bi-hormonal, dual-sensor artificial pancreas and evaluation during inpatient studies IEEE Transactions on Biomedical Engineering 61 10 2014 2569 2581
26. P.G. Jacobs, J. El Youssef, J.R. Castle, J.M. Engle, D.L. Branigan, and P. Johnson Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon Conference Proceedings:... Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2011 2011 397 400
27. A.H. Kadish Automation control of blood sugar. I. A servomechanism for glucose monitoring and control The American Journal of Medical Electronics 3 1964 82 86
28. K. Kumareswaran, M.L. Evans, and R. Hovorka Closed-loop insulin delivery: Towards improved diabetes care Discovery Medicine 13 69 2012 159 170
29. M. Lorenzi, N. Bohannon, E. Tsalikian, and J.H. Karam Duration of type I diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia Western Journal of Medicine 141 4 1984 467 471
30. D. Lv, M.D. Breton, and L.S. Farhy Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients Diabetes Technology & Therapeutics 15 11 2013 935 941
31. J.S. Pedersen, D. Dikov, J.L. Flink, H.A. Hjuler, G. Christiansen, and D.E. Otzen The changing face of glucagon fibrillation: Structural polymorphism and conformational imprinting Journal of Molecular Biology 355 3 2006 501 523
32. S.J. Russell, F.H. El-Khatib, D.M. Nathan, and E.R. Damiano Efficacy determinants of subcutaneous microdose glucagon during closed-loop control Journal of Diabetes Science and Technology 4 6 2010 1288 1304
33. S. Sjoberg, B. Ahren, and J. Bolinder Residual insulin secretion is not coupled to a maintained glucagon response to hypoglycaemia in long-term type 1 diabetes Journal of Internal Medicine 252 4 2002 342 351
34. G.J. Taborsky Jr., B. Ahren, and P.J. Havel Autonomic mediation of glucagon secretion during hypoglycemia: Implications for impaired alpha-cell responses in type 1 diabetes Diabetes 47 7 1998 995 1005
35. A.C. Van Bon, L.D. Jonker, R. Koebrugge, R. Koops, J.B. Hoekstra, and J.H. DeVries Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions Journal of Diabetes Science and Technology 6 5 2012 1114 1122
36. A.C. van Bon, Y.M. Luijf, R. Koebrugge, R. Koops, J.B. Hoekstra, and J.H. Devries Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours Diabetes Technology & Therapeutics 16 3 2014 131 136
37. W.K. Ward, J.R. Castle, and J. El Youssef Safe glycemic management during closed-loop treatment of type 1 diabetes: The role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia Journal of Diabetes Science and Technology 5 6 2011 1373 1380
38. W.K. Ward, J.M. Engle, D. Branigan, J. El Youssef, R.G. Massoud, and J.R. Castle The effect of rising vs. falling glucose level on amperometric glucose sensor lag and accuracy in type 1 diabetes Diabetic Medicine 29 8 2012 1067 1073